Historical Valuation
Kestra Medical Technologies Ltd (KMTS) is now in the Fair zone, suggesting that its current forward PS ratio of 13.07 is considered Fairly compared with the five-year average of -9.69. The fair price of Kestra Medical Technologies Ltd (KMTS) is between 13.80 to 24.90 according to relative valuation methord.
Relative Value
Fair Zone
13.80-24.90
Current Price：22.98
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Kestra Medical Technologies Ltd (KMTS) has a current Price-to-Book (P/B) ratio of 7.65. Compared to its 3-year average P/B ratio of 3.89 , the current P/B ratio is approximately 96.48% higher. Relative to its 5-year average P/B ratio of 3.89, the current P/B ratio is about 96.48% higher. Kestra Medical Technologies Ltd (KMTS) has a Forward Free Cash Flow (FCF) yield of approximately -8.04%. Compared to its 3-year average FCF yield of -8.83%, the current FCF yield is approximately -8.99% lower. Relative to its 5-year average FCF yield of -8.83% , the current FCF yield is about -8.99% lower.
Competitors Valuation Multiple
AI Analysis
The average P/S ratio for KMTS competitors is 4.87, providing a benchmark for relative valuation. Kestra Medical Technologies Ltd Corp (KMTS.O) exhibits a P/S ratio of 13.07, which is 168.15% above the industry average. Given its robust revenue growth of 53.40%, this premium appears sustainable.
Performance Decomposition
AI Analysis
1Y
3Y
5Y
Market capitalization of KMTS increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of KMTS in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is KMTS currently overvalued or undervalued?
Kestra Medical Technologies Ltd (KMTS) is now in the Fair zone, suggesting that its current forward PS ratio of 13.07 is considered Fairly compared with the five-year average of -9.69. The fair price of Kestra Medical Technologies Ltd (KMTS) is between 13.80 to 24.90 according to relative valuation methord.
What is Kestra Medical Technologies Ltd (KMTS) fair value?
KMTS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Kestra Medical Technologies Ltd (KMTS) is between 13.80 to 24.90 according to relative valuation methord.
How does KMTS's valuation metrics compare to the industry average?
The average P/S ratio for KMTS's competitors is 4.87, providing a benchmark for relative valuation. Kestra Medical Technologies Ltd Corp (KMTS) exhibits a P/S ratio of 13.07, which is 168.15% above the industry average. Given its robust revenue growth of 53.40%, this premium appears sustainable.
What is the current P/B ratio for Kestra Medical Technologies Ltd (KMTS) as of Jan 16 2026?
As of Jan 16 2026, Kestra Medical Technologies Ltd (KMTS) has a P/B ratio of 7.65. This indicates that the market values KMTS at 7.65 times its book value.
What is the current FCF Yield for Kestra Medical Technologies Ltd (KMTS) as of Jan 16 2026?
As of Jan 16 2026, Kestra Medical Technologies Ltd (KMTS) has a FCF Yield of -8.04%. This means that for every dollar of Kestra Medical Technologies Ltd’s market capitalization, the company generates -8.04 cents in free cash flow.
What is the current Forward P/E ratio for Kestra Medical Technologies Ltd (KMTS) as of Jan 16 2026?
As of Jan 16 2026, Kestra Medical Technologies Ltd (KMTS) has a Forward P/E ratio of -10.74. This means the market is willing to pay $-10.74 for every dollar of Kestra Medical Technologies Ltd’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Kestra Medical Technologies Ltd (KMTS) as of Jan 16 2026?
As of Jan 16 2026, Kestra Medical Technologies Ltd (KMTS) has a Forward P/S ratio of 13.07. This means the market is valuing KMTS at $13.07 for every dollar of expected revenue over the next 12 months.